CC-95251
Drug
Celgene Corporation
Total Payments
$590,869
Transactions
7
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $590,869 | 7 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $590,869 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 1- ST-001 Monotherapy escalation + escalation in combination with Cetux and Rituximab (CC-95251-ST-001) (BMS Study Number: CA059-P01) (CC-95251-ST-001) | Celgene Corporation | $590,869 | 0 |
Top Doctors Receiving Payments for CC-95251
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Scottsdale, AZ | $590,869 | 7 |
Ad
Manufacturing Companies
- Celgene Corporation $590,869
Product Information
- Type Drug
- Total Payments $590,869
- Total Doctors 0
- Transactions 7
About CC-95251
CC-95251 is a drug associated with $590,869 in payments to 0 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2019. In 2019, $590,869 was paid across 7 transactions to 0 doctors.
The most common payment nature for CC-95251 is "Unspecified" ($590,869, 100.0% of total).
CC-95251 is associated with 1 research study, including "Phase 1- ST-001 Monotherapy escalation + escalation in combination with Cetux and Rituximab (CC-95251-ST-001) (BMS Study Number: CA059-P01) (CC-95251-ST-001)" ($590,869).